4.7 Article

Glutamate neurocircuitry: theoretical underpinnings in schizophrenia

Journal

FRONTIERS IN PHARMACOLOGY
Volume 3, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2012.00195

Keywords

schizophrenia; dopamine hypothesis; glutamate hypothesis; NMDA receptor

Funding

  1. Astra Zeneca
  2. Biomarin
  3. Dainippon Sumitomo/Sepracor/Sunovion
  4. Eli Lilly
  5. Forest
  6. Genomind
  7. Merck/Schering Plough
  8. PamLabs
  9. Pfizer
  10. PGxHealth
  11. Servier
  12. Shire
  13. Torrent
  14. Trovis

Ask authors/readers for more resources

The Dopamine Hypothesis of Schizophrenia is actively being challenged by the NMDA Receptor Hypofunctioning Hypothesis of Schizophrenia. The latter hypothesis may actually be the starting point in neuronal pathways that ultimately modifies dopamine pathways involved in generating both positive and negative symptoms of schizophrenia postulated by the former hypothesis. The authors suggest that even this latter, NMDA receptor-based, hypothesis is likely too narrow and offer a review of typical glutamate and dopamine-based neurocircuitry, propose genetic vulnerabilities impacting glutamate neurocircuitry, and provide a broad interpretation of a possible etiology of schizophrenia. In conclusion, there is a brief review of potential schizophrenia treatments that rely on the etiologic theory provided in the body of the paper.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available